

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions of claims in the application.

1. (Currently amended) A therapeutic composition for the treatment or prophylaxis of ~~autoimmune conditions~~ arthritis, wherein the composition comprises a β -glucuronidase enzyme ~~an enzyme~~ and collagen ~~an immunogen~~, the β -glucuronidase enzyme and the collagen ~~immunogen~~ being present in the composition at a dose which provides a beneficial effect to an individual in need of treatment.

2-3. (Cancelled)

4. (Original) The composition of claim 3, wherein the β -glucuronidase enzyme is β -D-glucuronoside glucuronosohydrolase (Registry number EC 3.2.1.31).

5. (Original) The composition of claim 1, wherein the enzyme is present at a concentration of between 200 and 10,000 Fishman units/ml.

6. (Original) The composition of claim 1, wherein the enzyme is present at a concentration of between 0.5 and 2.5 mg/ml.

7. (Original) The composition of claim 1, wherein the composition further comprises a stabiliser and/or activator.

8. (Original) The composition of claim 7, wherein the stabiliser and/or activator is an inert proteinaceous moiety.

9. (Original) The composition of claim 7, wherein the stabiliser and/or activator is selected from the group consisting of protamine sulphate and 1,10 diamino decane.

10. (Original) The composition of claim 7, wherein the stabiliser and/or activator is present at a concentration of up to 20 mg/l.

11. (Currently amended) A therapeutic composition for the treatment or prophylaxis of ~~arthritis autoimmune conditions~~, the composition comprising[[,]] a β -glucuronidase ~~an~~ enzyme, collagen ~~an immunogen~~, a stabiliser and/or activator, the β -glucuronidase enzyme and the collagen ~~immunogen~~ being present in the composition at a dose which provides a beneficial effect to an individual in need of treatment, wherein the composition further comprises hydroxyl moieties.

12. (Original) The composition of claim 11, wherein the hydroxyl moieties are provided by sugars or diols.

13. (Original) The composition of claim 11, wherein the hydroxyl moieties are provided by 1,3 cyclohexane diol.

14. (Original) The composition of claim 11, wherein the hydroxyl moieties are present at a concentration of up to 20 $\mu\text{g/l}$.

15. (Previously presented) The composition of claim 1, wherein the composition is buffered to an acid or neutral pH.

16. (Original) The composition of claim 15, wherein the composition is buffered to a pH of between 5 and 6.

17. (Canceled)

18. (Original) The composition of claim 17, wherein the collagen is present at a concentration of between 10 and 1×10^{15} molecules/ml.

19. (Currently amended) The composition of claim 1, wherein the composition further comprises a glycosaminoglycan.

20. (Original) The composition according to claim 19, wherein the glycosaminoglycan is selected from the group consisting of hyaluronate (D glucuronic acid N acetyl D glucosamine), chondroitin sulphate (D glucuronic acid N acetyl D galactosamine 4 or 6 sulphate), dermatan sulphate (D glucuronic acid or L iduronic acid N acetyl D galactosamine), keratan sulphate (D galactose N acetyl D glucosamine sulphate), and heparan sulphate (D glucuronic acid or L iduronic acid N acetyl D glucosamine).

21. (Original) The composition of claim 19, wherein the glycosaminoglycan is chondroitin -6- sulphate.

22. (Original) The composition of claim 19, wherein the glycosaminoglycan is present at a concentration of between 0.1 and 1.0 mg/ml.

23. (Currently amended) The composition of claim 1, wherein the composition is in a formulation suitable for transdermal infusion or intradermal injection.

24. (Currently amended) A kit for preparing the composition of claim 1, wherein the kit comprises an β -glucuronidase ~~an~~-enzyme solution and a collagen ~~an immunogen~~ solution, and the two solutions are introduced to one another and allowed to admix prior to administration to an individual in need of treatment of arthritis.

25-28. (Cancelled)

29. (Previously presented) A composition comprising 1,000 to 5,000 Fishman units/ml β -glucuronidase, 6 μ g/ml protamine sulphate, 1 μ g/ml 1,3 cyclohexane diol, and 0.5 mg/ml chondroitin sulphate, buffered to pH 5.9 and a concentration of collagen selected from the group consisting of 2.5×10^{12} , 2.5×10^{10} and 2.5×10^4 molecules/ml for use in the treatment of rheumatoid arthritis.

30. (Currently amended) A method of using the composition of claim 1 or 11, for the treatment of arthritis.

31. (New) A method of using the composition of claim 29, for the treatment of arthritis.